Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA3 | O75311 | 1/20 | 0.57 |
| ▸ | GLRB | P48167 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | HNF4A | P41235 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122027 | 0.87 | GLRA3 (0.69) | GLRA3GLRBMEN1KMT2AGAA | |
| SCHEMBL2787696 | 0.87 | GLRA3 (0.53) | GLRA3GLRBMEN1KMT2APTGS1 | |
| SCHEMBL4125578 | 0.86 | GLRA3 (0.49) | GLRA3GLRBMEN1KMT2AGAA | |
| SCHEMBL2789396 | 0.86 | GLRA3 (0.49) | GLRA3GLRBPTPN5 | |
| SCHEMBL4128724 | 0.85 | GLRA3 (0.54) | GLRA3GLRBMEN1KMT2AGAA | |
| SCHEMBL2790755 | 0.85 | GLRA3 (0.50) | GLRA3GLRBCA2CA1CYP1A2 | |
| SCHEMBL2789471 | 0.85 | GLRA3 (0.50) | GLRA3GLRBMEN1KMT2AGAA | |
| SCHEMBL2790750 | 0.84 | GLRA3 (0.47) | GLRA3GLRBMEN1KMT2APTPN1 | |
| SCHEMBL2790732 | 0.84 | GLRA3 (0.47) | GLRA3GLRBAKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL4121457 | 0.84 | GLRA3 (0.47) | GLRA3GLRBCA2CA1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075932-A1 | NOVEL SALICYLIC ANILIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-03-25 | — | — | US | claimed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | claimed |
| US-7645791-B2 | Salicylic anilides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-01-12 | — | — | US | claimed |
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| US-20090005434-A1 | Novel Salicylic Anilides | NOVO NORDISK A/S (DK) | 2009-01-01 | — | — | US | claimed |
| EP-1890993-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | claimed |
| US-20070004794-A1 | Novel salicylic anilides | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | claimed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | claimed |
| WO-2006121390-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | claimed |
| EP-1689700-A1 | NOVEL SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | claimed |
| WO-2005051894-A1 | NOVEL SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | claimed |
| US-20100075932-A1 | NOVEL SALICYLIC ANILIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| US-7645791-B2 | Salicylic anilides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121390-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | disclosed |
| EP-1689700-A1 | NOVEL SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051894-A1 | NOVEL SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | GLRA1, GLRB, GPBAR1 | GLRA3 6/4885GLRB 2/4885MEN1 2512/4885 |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | GLRA3 1540/4885GLRB 1915/4885MEN1 4083/4885 |
| US-20090005434-A1 | Novel Salicylic Anilides | FABP4, ADIPOR1, ADIPOR2 | GLRA3 3975/4885GLRB 3413/4885MEN1 4710/4885 |
| US-20070004794-A1 | Novel salicylic anilides | FABP4, ADIPOR1, ADIPOR2 | GLRA3 3975/4885GLRB 3413/4885MEN1 4710/4885 |
| US-20100075932-A1 | NOVEL SALICYLIC ANILIDES | FABP4, ADIPOR1, ADIPOR2 | GLRA3 3975/4885GLRB 3413/4885MEN1 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.